24-Hour efficacy of once-daily desloratadine therapy in patients withseasonal allergic rhinitis [ISRCTN32042139]

BMC Family Practice

Volumn 3, Issue , 2002, Pages 1-6

  Salmun, Luis M ^a   Lorber, Richard ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 34248352628     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-3-14     Document Type: Article

References (12)

1. Brunton SA: Allergy management strategies: An update. Patient Care 2002, Spring(suppl):16-25
2. 1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000, 50:345-352
3. McClellan K, Jarvis B: Desloratadine. Drugs 2001, 61:789-796
4. Gupta S, Banfield C, Affrime M, Marbury T, Padhi D, Glue P: Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002, 41(suppl 1):7-12
5. Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J, Padhi D: Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 2002, 41(suppl 1):1-6
6. 1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons. Clin Drug Invest 2001, 21:25-32
7. Geha RS, Meltzer EO: Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001, 107:751-762
8. Ring J, Hein R, Gauger A, Bronsky E, Miller B, The Desloratadine Study Group: Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001, 40:1-5
9. Frossard N, Benabdesselam O, Melac M, Glasser N, Lacronique J, Pauli G: Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther 1998, 5:307-311
10. Grant JA, Riethuisen JM, Moulaert B, DeVos C: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002, 88:190-197
11. Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N: Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001, 86:387-392
12. Horak F, Stubner P, Zieglmayer R, Kavina A, De Vos C, Burtin B, Donnelly F: Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001, 125:73-79